{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77"}]}],"title":"Treatment-Emergent Adverse Event (TEAE)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63"}]}],"title":"Treatment-Related Adverse Event (TRAE)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}],"title":"Serious Adverse Event (SAE)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Related SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37"}]}],"title":"≥G3 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"≥G3 TRAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Infusion-related Reaction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"title":"TEAE of special interest"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"TEAE of special interest grade 3-5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"TEAE Leading to Death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"TEAE Leading to Drug Permanently Discontinued"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"TEAE Leading to Infusion Interruption"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}],"title":"TEAE Leading to Treatment Cycle Delay"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"groups":[{"description":"Participants received sugemalimab (CS1001) 1200 mg intravenously every 3 weeks (Q3W)","id":"OG000","title":"R/R ENKTL"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From enrollment to end of follow-up, a median of 29 months","title":"Number of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}